Business Segments

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Business Segments

Note 7. Business Segments

The Company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended September 30,
	2012			2011
Revenues
Vaccines/BioDefense	$	862,919		$	581,943
BioTherapeutics		68,708			5,213,919
Total	$	931,627		$	5,795,862
(Loss) Income from Operations
Vaccines/BioDefense	$	19,190		$	5,869
BioTherapeutics		(155,713	)		2,684,937
Corporate		(623,693	)		(487,343	)
Total	$	(760,216	)	$	2,203,463
Amortization and Depreciation Expense
Vaccines/BioDefense	$	31,357		$	11,247
BioTherapeutics		32,180			47,791
Corporate		495			559
Total	$	64,032		$	59,597
Interest Income, Net
Corporate	$	1,250		$	1,411
Stock-Based Compensation
Vaccines/BioDefense	$	29,103		$	16,998
BioTherapeutics		(49,275	)		60,487
Corporate		167,944			63,668
Total	$	147,772		$	141,153

	Nine Months Ended September 30,
	2012			2011
Vaccines/BioDefense	$	2,170,761		$	1,453,558
BioTherapeutics		171,135			5,556,129
Total	$	2,341,896		$	7,009,687
(Loss) Income from Operations
Vaccines/BioDefense	$	(111,319	)	$	5,921
BioTherapeutics		(1,363,572	)		(359,792	)
Corporate		(1,707,992	)		(1,098,302	)
Total	$	(3,182,883	)	$	(1,452,173	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	84,308		$	31,119
BioTherapeutics		86,913			132,282
Corporate		1,564			1,641
Total	$	172,785		$	165,042
Interest Income, Net
Corporate	$	5,284		$	5,319
Stock-Based Compensation
Vaccines/BioDefense	$	33,363		$	53,830
BioTherapeutics		63,339			346,995
Corporate		286,072			128,963
Total	$	382,774		$	529,788

	As of September 30,  2012		As of December 31, 2011
Identifiable Assets
Vaccines/BioDefense	$	556,020	$	689,266
BioTherapeutics		595,220		753,767
Corporate		3,921,820		6,780,625
Total	$	5,073,060	$	8,223,658